1.
Open Forum Infect Dis
; 9(10): ofac485, 2022 Oct.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36299530
RESUMEN
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.